#oral medication

Structure Therapeutics berichtet über ermutigende Phase-2-Ergebnisse für seinen oralen GLP-1-Rezeptor-Agonisten und bringt eine Tablettenform als Alternative zu injizierbaren Gewichtsverlust- und Diabetes-Medikamenten voran.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.